

# Amsterdam/Aarhus Chronic Thromboembolic Pulmonary Hypertension / Chronic Thromboembolic Disease (CTEPH/CTED) Cohort (2A3C) Study

Published: 13-06-2017

Last updated: 13-04-2024

Describe long-term changes in cardiorespiratory function and structure in a cohort of CTEPH and CTED patients treated with PEA and/or BPA in Denmark and the Netherlands.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Pulmonary vascular disorders
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON47632

### Source

ToetsingOnline

### Brief title

2A3C Study

### Condition

- Pulmonary vascular disorders

### Synonym

Chronic Thromboembolic Pulmonary Hypertension

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Vrije Universiteit Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Chronic Thromboembolic Pulmonary Hypertension, Hemodynamics, Magnetic Resonance Imaging

## Outcome measures

### Primary outcome

Main study parameters/endpoints: This is an observational study evaluating determinants of a persistent response to BPA or PEA. Main study parameter/endpoint is change in extracellular volume fraction after unloading of the RV after PEA or BPA. This is measured calculated from pre and post contrast T1 relaxation times measured by MR imaging.

### Secondary outcome

- Change in RV function and volumes after PEA or BPA. This is measured by MR imaging (RV ejection fraction, end diastolic volume, end systolic volume) and right heart catheterization (end systolic elastance, RV-Arterial coupling)
- Change in lung perfusion defects before and after PEA measured by MR perfusion
- Change in serum levels of biomarkers of fibrosis and extracellular matrix
- Change in platelet transcriptomes
- Change in exercise capacity (peak oxygen uptake during cardiopulmonary exercise testing, or CPET, and distance walked in 6 minutes) and gas exchange during CPET (ventilatory efficiency, pulse oximetry)
- Change in quality of life

- Change in diffusion capacity

## Study description

### Background summary

Rationale: In chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH), persistent thrombi after acute pulmonary embolism occlude the pulmonary vasculature and cause persistent perfusion defects in the lungs. Patients become symptomatic due to gas exchange abnormalities and pressure overload of the right ventricle (RV), either at rest or on exertion. A secondary pulmonary vasculopathy induced by high shear stress in non-obstructed vessels can contribute to further cardiorespiratory compromise. A diagnosis of CTEPH is a clear indication for interventional treatment, consisting of pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA), or pharmacological treatment when PEA and BPA are not possible or insufficient. Occluded vessels are opened by PEA and BPA and these interventions are also believed to lead to (partial) reverse remodelling of the lung vasculature and the RV. PEA and BPA can also be indicated for symptomatic CTED patients, who have persistent emboli but no signs of pulmonary hypertension. The early cardiorespiratory effects of BPA and PEA have been well described and it has become clear that residual pressure overload, RV dysfunction and gas exchange abnormalities are quite common. Little is known about the subsequent clinical course of residual pulmonary vascular and RV maladaptation after PEA and BPA. We have observed in our clinic both late reversal of pulmonary vascular and RV remodelling and recurrent adverse remodelling. We hypothesize that late reverse or adverse remodeling of the lung vasculature and RV are critical determinants of long-term clinical outcome in CTEPH and CTED. We also hypothesize that advanced imaging and biomarker analysis will allow for a better understanding of determinants of treatment success of PEA and BPA and that application of these methods will aid in recognition of those patients requiring additional (pharmacological) treatment.

### Study objective

Describe long-term changes in cardiorespiratory function and structure in a cohort of CTEPH and CTED patients treated with PEA and/or BPA in Denmark and the Netherlands.

### Study design

Study design: Prospective cohort study. CTEPH/CTED patients who are evaluated for invasive treatment with PEA or BPA will undergo structured follow up using right heart catheterization, MR imaging, quality of life questionnaire,

spirometry test, exercise testing and blood sampling before PEA or BPA, and again six and eighteen months after the last BPA session or day of surgery.

## **Study burden and risks**

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The study relies on information and results from procedures that are part of the clinical routine for CTEPH and CTED patients. This routine consists of the initial medical evaluation after referral and two follow-up visits six and eighteen months after PEA surgery or the last BPA procedure. Patients participating in the study will undergo an extended MR imaging protocol to assess RV function and lung perfusion, which includes administration of 0.3 mmol/kg of gadoterate meglumine contrast media. In rare cases, gadoterate meglumine may induce an allergic reaction. The patients will be informed about these risks and closely observed during the administration of the contrast agent. Milder, rare side effects of gadoterate meglumine are nausea, paraesthesias, skin irritation and headache. While a right heart catheterization is routinely done 3-6 months after PEA or BPA to assess the effects of the intervention, the 18 months\* right heart catheterization is currently only done in symptomatic patients (approximately one third of patients). In the last 15 years we have performed about 250 right heart catheterizations each year, with no significant complications. Occasionally, patients experience a local hematoma at the site of venous access in the internal jugular vein.

## **Contacts**

### **Public**

Vrije Universiteit Medisch Centrum

de Boelelaan 1117  
Amsterdam 1007 MB  
NL

### **Scientific**

Vrije Universiteit Medisch Centrum

de Boelelaan 1117  
Amsterdam 1007 MB  
NL

## **Trial sites**

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

- Diagnosis of CTEPH or CTED (according to ESC/ERS guidelines (11))
- Scheduled for evaluation to determine possibility of PEA or BPA
- Age > 18

### Exclusion criteria

- Pacemaker or other metal objects in the body
- Severe claustrophobia
- Severe renal insufficiency (eGFR < 30 mL/min)
- Allergy to gadolinium contrast
- Inability to provide informed consent

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 11-09-2017

Enrollment:	200
Type:	Actual

## Ethics review

Approved WMO	
Date:	13-06-2017
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	23-05-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL60598.029.17